Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 15.
doi: 10.1007/s10157-025-02696-7. Online ahead of print.

Trend of treatment strategy for amyloid light-chain amyloidosis: a-single center experience

Yoshifumi Ubara  1 , Kei Kono  2 , Junichi Hoshino  3 , Takehiko Wada  3 , Atsushi Wake  4 , Kenichi Ohashi  2   5 , Naoki Sawa  3
Affiliations
Review

Trend of treatment strategy for amyloid light-chain amyloidosis: a-single center experience

Yoshifumi Ubara et al. Clin Exp Nephrol. .

Abstract

Before 2000, AL amyloidosis was considered an incurable disease. However, in the 2000s, autologous peripheral blood stem cell transplantation therapy using vincristine + doxorubicin + dexamethasone with high-dose melphalan (VAD + SCT) was initiated. Bone marrow cells are the site of AL amyloid production. By normalizing bone marrow cells, VAD + SCT not only reduces amyloid production but also improves renal tissue damaged by amyloid deposition. However, VAD + SCT was only applied to patients who met the criteria, such as being under 65 years of age and not affecting the heart. At our hospital, VAD + SCT was applied in 20 patients who met this criteria. After treatment, 5 died and 2 required hemodialysis, but the remaining 13 patients survived for more than 10 years, with resolution of proteinuria and maintenance of renal function. These outcomes indicate that suppression of amyloid production is an effective treatment for AL amyloidosis. In the 2020s, molecularly targeted drugs against the plasma cell CD38 began to be administered for the treatment of AL amyloidosis.

Keywords: AL amyloidosis; DaraCyBorD (daratumumab plus cyclophosphamide, Bortezomib and dexamethasone); VAD + SCT; Vincristine plus doxorubicin plus dexamethasone (VAD) + high-dose melphalan and autologous peripheral blood stem cell transplantation combination (SCT).

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing financial interests and no conflicts of interest. Ethical approval: The present report was produced in conformity with the Declaration of Helsinki.

Similar articles

See all similar articles

References

    1. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–7. - DOI - PubMed
    1. Senot N, Gibier JB, Rabant M, Esteve E, Ferriere E, Dessaix K, Colombat M, Perrochia H, Olagne J, Goujon JM, Wayolle N, Wemeau M, Carpentier B, Pinson P, Beeker N, Bridoux F, Cohen C. Epidemiological and clinicopathological characteristics of vascular-limited renal AL amyloidosis. Nephrol Dial Transplant. 2024. https://doi.org/10.1093/ndt/gfae285 . - DOI - PubMed
    1. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276–82. - DOI - PubMed
    1. Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42:72–7. - DOI - PubMed
    1. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid. 2004;11:245–56. - DOI - PubMed

LinkOut - more resources